PFE vs BIIB — Key Metrics

Metric PFE (PFIZER INC) BIIB (BIOGEN INC)
Price28.06251.41
Market Cap159.94 Billion37.16 Billion
P/E (TTM)39.52106.53
P/B (Quarterly)1.9211.907
P/S (TTM)2.513.61
Net Profit Margin (TTM)6.33.4
Gross Margin (TTM)73.474.0
ROE (TTM)4.61.9
Revenue Growth YoY (TTM)n/an/a

Upfront Investment - S&P 500 Stock Comparison & AI Analysis

AI-powered analysis and comparison tools for S&P 500 stocks, helping investors make data-driven decisions with delayed market data and portfolio modeling.

PFIZER INC
vs
 
BIOGEN INC
 
PFIZER INC
vs
 
BIOGEN INC
Performance Comparison
AI Model Recommendation
PFE · PFIZER INC

Greatly Outperform

91
UnderperformOutperform
BIIB · BIOGEN INC

Greatly Outperform

76
UnderperformOutperform
Recommendation Summary

Both stocks are projected to significantly outperform the market over the next year. If you have to make a choice, Upfront Recommendation: PFE.

Financial Metrics
Prices delayed ~15 min
PFE Metrics BIIB
$28.06 Price $251.41
— Market Capitalization —
39.52 Price to Earnings Ratio 106.53
2.51 Price to Sales 3.61
13.57 Price to FCF Ratio 18.09
3.43 Price to Gross Profit 4.88
13.88 Price to R&D 17.27
3.55 Price to Current Assets 4.9

PFE vs BIIB at a glance

Pfizer INC (PFE) and Biogen INC (BIIB) are both Drug Manufacturers - General companies in the Healthcare sector. PFE is the larger, at $159.9 billion in market value against $37.2 billion for BIIB, about 4.3 times the size.

On trailing-twelve-month figures, PFE trades at 39.5 times trailing earnings and BIIB at 106.5; net profit margins are 6.3% and 3.4%.

The Upfront Investment model currently rates both Greatly Outperform as of November 18, 2026. The rating ranks the model's medium-term return forecast against the other stocks it scores; it is a statistical forecast, not investment advice.